Literature DB >> 423486

Elimination of ampicillin and gentamicin by hemofiltration.

D Kraft, H Lode.   

Abstract

Elimination of ampicillin and gentamicin by hemofiltration was measured in 5 and 4 patients, respectively, being treated for end stage renal failure. Serum half-life time of ampicillin after a single I.V. dose of 2 g, was found to be 2.97 +/- 0.73 h, and the filtrate concentrations declined parallel to the serum ampicillin levels, as was to be expected. The serum half-life time after a single I.V. dose of 1 mg/kg body weight gentamicin was 3.26 +/- 0.42 h, and considerably shorter than T/2 of gentamicin in conventional hemodialysis, while the filtrate concentrations increased paradoxically with declining serum levels. This could be explained by binding of this aminoglycoside to the polyacrylnitril membrane of the RP 6 dialyser used for hemofiltration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 423486     DOI: 10.1007/bf01477408

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  4 in total

1.  Binding of antibiotics by dialysis membranes and its clinical relevance.

Authors:  K W Rumpf; J Rieger; R Ansorg; B Doht; F Scheler
Journal:  Proc Eur Dial Transplant Assoc       Date:  1977

2.  Pharmacokinetics of gentamicin and kanamycin during hemodialysis.

Authors:  M Danish; R Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

3.  Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality.

Authors:  L W Henderson; C K Colton; C A Ford
Journal:  J Lab Clin Med       Date:  1975-03

4.  [Ampicillin level in serum and urine in decreased kidney function].

Authors:  D Höffler; I Stegemann; F Scheler
Journal:  Dtsch Med Wochenschr       Date:  1966-02-04       Impact factor: 0.628

  4 in total
  9 in total

1.  Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.

Authors:  Qi Tian; Charles D Gomersall; Margaret Ip; Perpetua E Tan; Gavin M Joynt; Gordon Y S Choi
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

2.  In vitro adsorption of gentamicin and netilmicin by polyacrylonitrile and polyamide hemofiltration filters.

Authors:  Philip K N Lam; Qi Tian; Margaret Ip; Charles D Gomersall
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

Review 3.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

Review 4.  Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.

Authors:  T A Golper; W M Bennett
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 5.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.

Authors:  J M Kinowski; J E de la Coussaye; F Bressolle; D Fabre; G Saissi; O Bouvet; M Galtier; J J Eledjam
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 7.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 8.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 9.  Treatment with echinocandins during continuous renal replacement therapy.

Authors:  Francisco González de Molina; Maria de Los Ángeles Martínez-Alberici; Ricard Ferrer
Journal:  Crit Care       Date:  2014-03-28       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.